# Analysis of the Duration of Combination Therapy That is Necessary for HCV Genotype 1 Eradication

> **NCT00152581** · PHASE4 · COMPLETED · sponsor: **University College London Hospitals** · enrollment: 40 (—)

## Conditions studied

- Chronic Hepatitis C, HCV Genotype 1

## Interventions

- **DRUG:** Pegylated interferon-alfa2a (Pegasys); ribavirin

## Key facts

- **NCT ID:** NCT00152581
- **Lead sponsor:** University College London Hospitals
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 40 (—)
- **Last updated:** 2005-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00152581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00152581, "Analysis of the Duration of Combination Therapy That is Necessary for HCV Genotype 1 Eradication". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00152581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*